Breaking News
January 22, 2019 - Better mouse model built to enable precision-medicine research for Alzheimer’s
January 22, 2019 - Molecular profiling of precancerous lung lesions could lead to early detection and new treatments
January 22, 2019 - Genetic factors influence where fat is stored in our bodies
January 22, 2019 - The Psychology Behind Sticking to Your New Year’s Resolutions
January 22, 2019 - Scientists aim to find genetic causes of developmental abnormalities in the vagina and uterus
January 22, 2019 - Looming Global Crisis Means People’s Diets Must Change: Experts
January 22, 2019 - Excessive social media use is comparable to drug addiction
January 22, 2019 - Researchers show how mechanical stress affects bone development
January 22, 2019 - Study takes a step closer to understanding the body’s response to opioid painkillers
January 22, 2019 - Unexpected connection found between feeding and memory centers of the brain
January 22, 2019 - A revolutionary approach transforms bone trauma treatment
January 22, 2019 - Early studies and recent clinical trials on nerve growth factor
January 22, 2019 - Dry Mouth and Older Adults: Information for Caregivers
January 22, 2019 - Are your grandparents getting tipsy at the holiday party?
January 22, 2019 - New machine learning algorithms identify early symptoms of urinary tract infections
January 22, 2019 - Young women skipping the Pap smear test due to embarrassment
January 22, 2019 - A global influenza pandemic high on the WHO’s agenda
January 22, 2019 - Amgen Makes All Repatha (evolocumab) Device Options Available In The US At A 60 Percent Reduced List Price
January 22, 2019 - Elastronics—hydrogel-based microelectronics for localized low-voltage neuromodulation
January 22, 2019 - Branched-chain amino acids in tumors can be targeted to prevent and treat cancer
January 22, 2019 - Fueling macrophages with energy to attack and eat cancer cells
January 22, 2019 - Amgen And UCB Receive Positive Vote From FDA Advisory Committee In Favor Of Approval For Evenity (romosozumab)
January 22, 2019 - Does being bilingual make children more focused? Study says no
January 22, 2019 - Study reveals new genes and biological pathways linked to osteoarthritis
January 22, 2019 - FSU study provides better understanding of spinal cord injuries
January 22, 2019 - Delaying bath for newborn babies increases breastfeeding rates, finds study
January 21, 2019 - WHO identifies non-communicable diseases as major threat to human health
January 21, 2019 - Many parents still try non-evidence-based cold prevention methods for children
January 21, 2019 - High Levels of Activity, Motor Ability Linked to Better Cognition
January 21, 2019 - Killer blows? Knockout study of pair of mouse MicroRNA provides cancer insight
January 21, 2019 - Buffalo researchers receive grant to quicken development of generic equivalents of contraceptives
January 21, 2019 - One-third of pregnant women do not believe cannabis is harmful to their fetus
January 21, 2019 - Fiderstat could be used as chemopreventative drug for intestinal cancers caused by APC gene mutations
January 21, 2019 - Modifying healthcare delivery practices may improve discussions between youth and healthcare providers
January 21, 2019 - UNIST researcher named as recipient of Merck’s 2018 Life Science Awards
January 21, 2019 - How Getting a Flu Shot Could Save Your Life
January 21, 2019 - Surgical adhesions can be treated, prevented in mice
January 21, 2019 - Increased physician-targeted marketing associated with higher opioid overdose deaths
January 21, 2019 - Researchers uncover specific microbial signatures of intestinal disease
January 21, 2019 - Researchers discover new blood vessel system in bones
January 21, 2019 - Simple blood test reliably detects signs of Alzheimer’s damage before symptoms
January 21, 2019 - Study to investigate new targeted oral treatments for severe asthma
January 21, 2019 - Plan Your Plate | NIH News in Health
January 21, 2019 - Fecal occult blood test may improve CRC outcomes in some
January 21, 2019 - Blood test detects Alzheimer’s disease years before symptoms develop
January 21, 2019 - Mount Sinai joins with Paradigm and ReqMed to repurpose drug for treatment of MPS
January 21, 2019 - FDA Advisory Committee Votes on Zynquista (sotagliflozin) as Treatment for Adults with Type 1 Diabetes
January 21, 2019 - The causes and complications of snoring
January 21, 2019 - Placenta adapts and compensates when pregnant mothers have poor diets or low oxygen
January 21, 2019 - New implant could restore the transmission of electrical signals in injured central nervous system
January 21, 2019 - Rapid-acting fentanyl test strips found to be effective at reducing overdose risk
January 21, 2019 - Coronary Artery Calcium May Help Predict CVD in South Asians
January 21, 2019 - The mystery of the super-ager
January 21, 2019 - Scientists develop smart microrobots that can change shape depending on their surroundings
January 21, 2019 - Keep Moving to Keep Brain Sharp in Old Age
January 21, 2019 - Despite progress, gay fathers and their children still structurally stigmatized
January 21, 2019 - New drug for treating liver parasites in vivax malaria
January 21, 2019 - Merck recognized with 2018 Life Science Industry Award for best use of social media
January 21, 2019 - Coeur Wallis equips the canton of Valais with 260 SCHILLER defibrillators
January 21, 2019 - Scientists propose quick and pain-free method for diagnosing kidney cancer
January 21, 2019 - Signs of memory loss could point to hearing issues
January 21, 2019 - HeartFlow Analysis shows highest diagnostic performance for detecting coronary artery disease
January 21, 2019 - How Much Caffeine is Too Much?
January 21, 2019 - Take a timeout before you force your child to apologize
January 21, 2019 - Scientists design two AI algorithms to improve early detection of cognitive impairment
January 21, 2019 - Novel therapy for children with chronic hormone deficiency provides lifeline for parents
January 21, 2019 - Bioethicists call for oversight of poorly regulated, consumer-grade neurotechnology products
January 21, 2019 - Study shows hereditary hemochromatosis behind many cancers and joint diseases
January 21, 2019 - Short bouts of stairclimbing throughout the day can improve cardiovascular health
January 20, 2019 - Liver Transplant Survival May Improve With Race Matching
January 20, 2019 - Study implicates hyperactive immune system in aging brain disorders
January 20, 2019 - Cancer Diagnosis May Quadruple Suicide Risk
January 20, 2019 - Parkinson’s disease experts devise a roadmap
January 20, 2019 - Research brings new hope to treating degenerative brain diseases
January 20, 2019 - Scientists pinpoint a set of molecules that wire the body weight center of the brain
January 20, 2019 - Researchers get close to developing elusive blood test for Alzheimer’s disease
January 20, 2019 - UCLA researchers demonstrate new technique to develop cancer-fighting T cells
January 20, 2019 - Researchers discover how cancer cells avoid genetic meltdown
January 20, 2019 - Exercise makes even the ‘still overweight’ healthier: study
January 20, 2019 - University of Utah to establish first-of-its-kind dark sky studies minor in the US
Delays Raise Death Risk in Kids with Status Epilepticus

Delays Raise Death Risk in Kids with Status Epilepticus

image_pdfDownload PDFimage_print

Action Points

  • Delay of ≥10 minutes after seizure onset in first-line benzodiazepine treatment of pediatric patients with refractory convulsive status epilepticus (SE) is associated with adverse short-term outcomes, including death, more frequent use of continuous infusions, longer seizure duration, and more frequent hypotension.
  • Note that these findings may change the perception of acute seizure and SE treatment, converting it into an extremely time-sensitive emergency similar to stroke or other cardiovascular events.

Delayed first-line treatment of refractory convulsive status epilepticus (SE) led to a higher frequency of death, a 5-year observational study from the Pediatric Status Epilepticus Research Group found.

Pediatric patients who received first-line benzodiazepine treatment 10 minutes or more after SE onset had a much higher chance of death (adjusted OR 11.0), greater odds of receiving continuous infusion (adjusted OR 1.8), longer convulsive seizure durations (adjusted OR 2.6), and more frequent hypotension (adjusted OR 2.3), reported Tobias Loddenkemper, MD, director of Clinical Epilepsy Research at Boston Children’s Hospital. and colleagues.

First-line treatment delays also were linked to delays in administering second- and third-line treatments.

“These findings may change the perception of acute seizure and status epilepticus treatment, tentatively converting it into an extremely time-sensitive emergency that is similar to stroke or other cardiovascular events,” the team wrote online in JAMA Neurology.

“This is the first pediatric study on refractory convulsive SE that demonstrates a link between delayed treatment and poor outcomes and suggests that timely treatment may be a method to prevent or improve such outcomes,” commented Anup D. Patel, MD, section chief of Neurology at Nationwide Children’s Hospital in Columbus, OH, writing in an accompanying editorial.

“Status epilepticus is life threatening and affects a high percentage of children. Both short-term and long-term morbidity and mortality risks are present for children who experience SE. Methods to improve these outcomes are thus desperately needed.”

Current SE treatment protocols recommend that patients receive first-line treatment — a benzodiazepine — within 5 to 10 minutes of seizure onset. This usually is followed by a second-line treatment of a non-benzodiazepine anti-seizure medication 10 to 20 minutes later. If SE persists, patients may receive a third-line treatment — anesthetic agents by continuous infusion — within 30 to 70 minutes of seizure onset.

The rationale is to stop seizures quickly and reduce the risk of brain damage and other complications. Studies have shown that seizures usually last less than 10 minutes; seizures lasting longer often do not stop spontaneously.

While time to treatment has been associated independently with SE duration, the effects on other outcome measurements like death were unknown.

To discover how timing mattered, Loddenkemper et al performed an observational study of 218 children admitted with refractory convulsive SE to 11 pediatric tertiary hospitals in the United States from June 1, 2011, to July 31, 2016. Patients were stratified into two groups: those who received timely first-line benzodiazepine (i.e., given within less than 10 minutes of seizure onset); and those who received treatment within 10 or more minutes.

Patients were ages 1 month to 21 years, had focal or generalized convulsive epileptic seizures at onset, and had treatment failure with two or more anti-seizure medications or started continuous infusion for seizure control.

The median age of the group was 4, and 53.2% were male. Of the 218 patients studied, 33.9% received first-line benzodiazepine treatment in less than 10 minutes, and 66.1% received it in 10 minutes or more. In 63.8% of patients, refractory convulsive SE started in a pre-hospital setting.

The median time to first-line benzodiazepine treatment was 17 minutes; it was longer in the pre-hospital group than the in-hospital cohort (25 minutes versus 8 minutes). The median time to the first administration of non-benzodiazepine anti-seizure medications was 63 minutes — that, too, was longer for the pre-hospital group (82 minutes) than the in-hospital group (40 minutes).

During hospital admission, seven patients (3.2%) died. All seven received untimely first-line benzodiazepine treatment, and five of the seven had pre-hospital SE onset. Multivariate analysis showed that untimely first-line benzodiazepine treatment had an adjusted OR of death of 11.0 (95% CI 1.43 to ∞; P=0.02.).

About half of the patients in the study — 112, or 51.4% — received a continuous infusion; of these, 71.4% had received untimely first-line treatment (P=0.09). The untimely treatment group was more likely to receive one or more continuous infusions (adjusted OR, 1.8; 95% CI 1.01-3.36; P=0.047).

The median convulsion duration was 48.5 minutes longer for patients who received untimely first-line benzodiazepine treatment (91 versus 139.5 minutes; P=0.03).

More work is needed to improve outcomes, especially in the pre-hospital setting, Patel noted: “Evidence-based guidelines exist for the pre-hospital treatment of seizures and most emergency medical services have independent protocols, but it is not known if these guidelines are implemented uniformly by emergency medical services personnel.

“Standardization of these protocols using guidelines may improve outcomes and is a good first step.”

The study has several limitations, the researchers noted. They did not determine the association between the dose of benzodiazepine and outcomes, and the small number of overall deaths in the study limited the number of confounders in the analysis; other confounders may have influenced mortality and other outcomes. In the pre-hospital setting, times to treatment were based on information provided by families, although the researchers corroborated data with emergency medical services reports and medical records when available.

In addition, the team said, the findings do not include patients whose seizures spontaneously stopped, or stopped after medication before coming to the hospital; the findings apply only to pediatric patients with refractory convulsive SE.

The study and the Pediatric Status Epilepticus Research Group consortium of 11 tertiary pediatric hospitals in the United States are funded by the Epilepsy Research Fund and the Pediatric Epilepsy Research Foundation.

The researchers reported financial relationships with Ovation Pharmaceuticals, King Pharmaceuticals, PRA International/Eisai, Johnson & Johnson, Lily, GlaxoSmithKline, Pfizer, Siemens, General Electric, Supernus, AssureX Health, Sage Therapeutics, GWPharm, Novartis, Lundbeck, Upsher-Smith, Acorda, and Zogenix.

Patel reported financial relationships with Greenwich Biosciences, UCB Pharma, Supernus, LivaNova, and Upsher-Smith.

2018-01-23T14:00:00-0500

Tagged with:

About author

Related Articles